anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Hematomas of the liver graft, that is, postintervention, subcapsular or intrahepatic are rare yet potentially fatal complications following liver transplantation (LT), necessitating immediate diagnosis and management to avert devastating outcomes. This study was aimed to introduce our approach to manage graft hematoma subsequent to LT.
METHODS: Among 131 orthotopic liver transplantations (OLT) conducted at our institution between January 2017 and May 2023, 3 cases of intrahepatic (n = 2) and extrahepatic (n = 1) hematoma were confirmed through computed tomography (CT) within 10 days after LT. The clinical outcomes of various treatment modalities for these three cases were analyzed.
RESULTS: Three out of 131 (2.3%) LT recipients developed graft hematoma. Patient 1 developed a spontaneous intrahepatic hematoma, without evident predisposing factors, while patient 2 developed an intrahepatic hematoma following endoscopic retrograde cholangiopancreatography (ERCP). The third case that is extrahepatic hematoma was speculated to be a result of minor hepatic parenchymal injury stemming from compressive and volume-reducing manipulation of a large graft, or secondary to focal ischemic necrosis of the liver. Our management protocol was summarized as follows: (1). Immediate ultrasound and CT, particularly enhanced CT; (2). Puncture and percutaneous drainage (PD) of the hematoma; (3). Arterial embolization if the origin could be identified as a ruptured vessel; (4). Surgical evacuation of the hematoma in the presence of bile leakage, to avoid a compartment respectably secondary infection. All three patients responded favorably to treatment and remained alive to date.
CONCLUSION: Prompt diagnosis and sequential individualized management can successfully deal with intra-/extrahepatic graft hematoma after LT. Our results underscored that an individualized management considering potential future complications into account.
Patients with AF, hospitalized in one of the 6 geriatrics units participating in the study, aged 75 years or over, without evaluation of their antithrombotic treatment by the multidisciplinary team. The lack of review of patient's file by the multidisciplinary team is based on physician decision.
PURPOSE:To lyophilize a small amt. of sample securely and to prevent deterioration of the sample by freezing liquid contg. the sample to form semispherical drops on a cooling plate and drying the frozen drops under reduced pressure. CONSTITUTION:Liquid contg. a sample comprising solution or suspension, etc. is dropped onto a plate cooled by liquid N2, etc. to such low temp. as capable of freezing the liquid instantly to semispherical frozen product, and the frozen product is further dried under reduced pressure at <=0 deg.C. Thus, a lyophilized product contg. desired agglutination activity units or desired units of weight, activity, or number of cell per dose, for red cell may be obtd. Further, since the product is lyophilized instantly due to its small surface area and dried without changing its shape, even easily deactivated samples such as virus can be lyophilized without deteriorating its activity with sufficient solubility preserved until it is renatured. Moreover, deterioration of the sample is held to the least degree since the sample does not directly contact a refrigerant at extremely low temp.
A hot or cold compress a layer of substituted urea/urethane hydrogel material bonded to a porous substrate. The hydrogel material is made up of a high molecular weight polyol, a toluene diisocyanate prepolymer and water. Generally, the water and polyol each comprises between about 40 to 50% by weight of the hydrogel, with the diisocyanate prepolymer making up the remaining 12-16% by weight. The hot or cold compresses of the present invention are formed by preparing the hydrogel material and then placing a porous substrate in contact with the hydrogel prior to the time that gel formation is complete. In this manner, the hydrogel becomes integrally bonded to the porous substrate. Other materials such as terrycloth can be bonded to the porous substrate prior to bonding the substrate to the hydrogel. Articles useful in therapy can then be formed by attaching the edges of the cloth/porous substrate to form the desired object.
These stem cells are called Human Spinal Stem Cells (HSSC) and have been engineered from the spinal cord of a single fetus electively aborted after 8 weeks of gestation. The tissue was obtained with the mother's consent. The cells will be transplanted into the ALS patient's spinal cord after laminectomy, an operation that removes bone surrounding the spine. After the spinal cord is exposed, a device manufactured for this purpose will be mounted onto the patient and will hold a syringe filled with the cells. The syringe will have a needle attached and the needle will enter the spinal cord in specified areas. The device will minimize trauma to the spinal cord by the needle by making the puncture precise and steady and injecting the material at a slow and steady speed.

ALS is a universally fatal neurodegenerative condition that causes weakness leading to paralysis and death. Life expectancy is 2-5 years. The cause is unknown and there is no effective treatment. Previous research has shown that on autopsy, ALS patients are found to have increased levels of the amino acid glutamate accumulated in the brain and spinal cord. This increase is thought to be caused by a decrease in the glutamate transporter which normally "cleans up" glutamate from the cells.

Because the HSSC are human in origin, their transplantation will be handled in some ways like other organ transplants in that patients will receive immunosuppressive medications to prevent the rejection of the cells. Right before and immediately after surgery patients will receive infusions of a drug called basiliximab. After surgery they will take prednisone and be tapered off that medication over one month. They will also be given two other immunosuppressive agents, tacrolimus and mycophenolate mofetil after surgery and it is expected that the patients will take these drugs for the rest of their lives.
Skin-associated autoimmune diseases are common these days. A method and composition for microbiome based amelioration of skin associated autoimmune inflammatory diseases has been provided. The composition is made of at least one or more of microbiome-associated compounds such as proteins, metabolites, antibiotics, probiotics, etc. The method provides a composition for an affected individual through application of these compositions aimed at improving the bioavailability of lipoic acid. It acts through modulation of the lipoic acid metabolic pathway to do the same. The suggested microbes and compounds can either be used as an effective probiotic supplement in increasing the microbial population involved in lipoic acid biosynthesis (only), or increasing the number of competitors of the microbes involved in escalation of lipoic acid salvage system, or through direct antibiotic or physical action against the latter.
Mounting evidence suggests that a metabolic defect exists in autosomal dominant polycystic kidney disease (ADPKD), which likely contributes to cystic epithelial proliferation and subsequent cyst growth. There are notable overlapping features and pathways among metabolism, obesity, and/or ADPKD. The investigators recently reported that in the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Study A that overweight and obesity are strong independent predictors of more rapid kidney growth. Moving beyond body mass index, the investigators have novel preliminary data using magnetic resonance images (MRIs) from a small number of participants from HALT-PKD Study A that abdominal adiposity is an independent predictor of kidney growth and kidney function decline. Adipocytes do not simply act as a fat reservoir but are active endocrine organs that promote release of pro-inflammatory cytokines and produce adipokines. Numerous signaling pathways promoted by adipocytes are also implicated in cystogenesis. Periods of fasting may counter adiposity-mediated signaling pathways and slow ADPKD progression. Mild-to-moderate food restriction profoundly slows cyst growth and maintains renal function in rodent models of ADPKD, which are characterized by metabolic reprogramming favoring enhanced aerobic glycolysis. Notably, fasting promotes a shift from carbohydrate to fat metabolism, which could suppress cyst growth. The investigators are currently conducting an ongoing behavioral weight loss pilot trial (based on either daily caloric restriction or intermittent fasting) in adults with ADPKD who are overweight/obese. As an alternative to these approaches, time-restricted feeding (TRF) is a novel fasting regimen that restricts eating to a feeding window (typically 8-12 hrs/day). As isocaloric TRF reduces disease progression in a rodent model of ADPKD, including kidney: body weight and mammalian target of rapamycin (mTOR) activity, it may be an alternative and easier to adhere to dietary strategy to slow ADPKD progression. Specific Aim: Determine the feasibility of TRF without energy intake restriction in adults with ADPKD and overweight/obesity. The study will determine adherence to TRF by assessing the percent of participants achieving the goal of eating within an 8-hour TRF window, measured objectively with a photographic food record and verified with continuous glucose monitoring data. The study will also further assess the safety, acceptability, and tolerability of TRF by evaluation of safety labs, adverse events, and quality of life measures, as well as changes in abdominal adiposity and total kidney volume (TKV) by magnetic resonance imaging (MRI), and markers of biological pathways (AMP-activated protein kinase \[AMPK\], mTOR, insulin-like growth factor 1 \[IGF1\]).
Alzheimer´s disease (AD) stands out as the most common chronic neurodegenerative disorder. AD is characterized by progressive cognitive decline and memory loss, with neurodegeneration as its primary pathological feature. The role of neuroinflammation in the disease course has become a focus of intense research. While microglia, the brain's resident macrophages, have been pivotal to study central immune inflammation, recent evidence underscores the contributions of other cellular entities to the neuroinflammatory process. In this article, we review the inflammatory role of microglia and astrocytes, focusing on their interactions with AD's core pathologies, amyloid beta deposition, and tau tangle formation. Additionally, we also discuss how different modes of regulated cell death in AD may impact the chronic neuroinflammatory environment. This review aims to highlight the evolving landscape of neuroinflammatory research in AD and underscores the importance of considering multiple cellular contributors when developing new therapeutic strategies.
7969. Teichmann, E., and Braun, H. April 2. Toxines, antitoxines, and like bacterial products.-A preparation for giving immunity against trypanosomes and other pathogenous micro-organisms is made by bleeding an infected animal while the infection is at its height, separating the trypanosomes from the blood and drying them. The trypanosomes may be separated by collecting the infected blood in a mixture of agglutinating antiserum, such as horse-serum, and a physiological solution of salt, so that the red corpuscles are precipitated, subjecting the supernatant liquid to centrifugal action in order to precipitate any remaining red corpuscles and separate the trypanosomes in a layer from the liquid, washing the separated trypanosomes in a solution of salt, and drying them, whereby a powder is produced that can be injected in a physiological solution of salt. To make a preparation capable of giving immunity against infection by flies, the flies, cultivated from larvae free from trypanosomes, are allowed to appropriate trypanosomes, and are kept alive for some time to allow the trypanosomes to undergo change. The flies are then washed in a solution of salt, and the mixture is injected into a rat &c. From the infected rat the stock of blood for the preparation of the powder as above described is obtained. Another preparation, capable of giving greater immunity, is made by injecting an animal repeatedly with the above-described preparation, extracting the serum containing antibodies from this animal, injecting another animal, such as a mouse, with this serum in quantity insufficient to destroy all the live trypanosomes subsequently injected, and then injecting the live trypanosomes. Another mouse is then injected with the antibodies and afterwards with the trypanosomes which have escaped death in the first mouse. This procedure is continued until the trypanosomes have become immune, and from this stock of trypanosomes a preparation is made as described above, and may be used in conjunction with the first preparation. The preparations may be agitated with toluene before injection in order to disinfect them, the toluene being then evaporated.
Walker-256 tumor is an experimental model known to promote cachexia syndrome, oxidative stress, and systemic inflammation. This study evaluated the duodenal mucosa of rats with Walker-256 tumor administered with 1% L-glutathione, intending to evaluate the damage caused by cancer-associated cachexia in the gastrointestinal tract and the effects of antioxidant administration on mucosal protection. Twenty-four 55-day-old male Wistar rats were distributed into four groups: control (C); control administered with 1% L-glutathione (C-GSH); Walker-256 tumor (W) and Walker-256 tumor administered with 1% L-glutathione (W-GSH). After 14 days of treatment, the duodenum was harvested for morphometric analysis of the mucosa, proliferation, apoptosis, immunostaining of varicosities immunoreactive (IR) to vasoactive intestinal peptide (VIP) and 5-HT-IR cells, and quantification of mast cells and goblet cells. Walker-256 tumor-bearing rats showed cachexia syndrome, mucosal atrophy, reduced cell proliferation, reduced 5-HT-IR cells, and increased goblet cells and VIPergic varicosities, which were not reversed by L-glutathione. On the other hand, L-glutathione caused a reduction of cells in apoptosis and mast cell recruitment, demonstrating a partial recovery of the damage detected in the intestinal mucosa.
Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
A pharmaceutical composition for treating, inhibiting, or preventing cancer can include an indole-3-carbinol derivative compound in a pharmaceutically acceptable carrier that is configured for oral administration. The indole-3-carbinol derivative compound can have antitumor activity, and oral administration can provide blood bioavailability of about 0.5% to about 25%. The pharmaceutically acceptable carrier can include a hydroxyl-fatty acid PEG monoester and/or diester. The carrier can be a hydroxyl-fatty acid PEG ester that includes 12-hydroxy stearate. The carrier can be a hydroxyl-fatty acid PEG ester that includes a PEG having from about 100 MW to about 200,000 MW. The indole-3-carbinol derivative can be 2,10-dicarbethoxy-6-methoxy-5,7-dihydro-indolo-(2,3-b)carbazole.
BACKGROUND AND AIMS: The structure-function relationships of high-density lipoprotein (HDL) subpopulations are not well understood. Our aim was to examine the interrelationships between HDL particle proteome and HDL functionality in subjects with and without coronary heart disease (CHD).
METHODS: We isolated 5 different HDL subpopulations based on charge, size, and apolipoprotein A1 (APOA1) content from the plasma of 33 overweight/obese CHD patients and 33 age-and body mass index (BMI)-matched CHD-free subjects. We measured the relative molar concentration of HDL-associated proteins by liquid chromatography tandem mass spectrometry (LC-MS/MS) and assessed particle functionality.
RESULTS: We quantified 110 proteins associated with the 5 APOA1-containing HDL subpopulations. The relative molar concentration of these proteins spanned five orders of magnitude. Only 10 proteins were present in >1% while 73 were present in <0.1% concentration. Only 6 of the 10 most abundant proteins were apolipoproteins. Interestingly, the largest (α-1) and the smallest (preβ-1) HDL particles contained the most diverse proteomes. The protein composition of each HDL subpopulation was altered in CHD cases as compared to controls with the most prominent differences in preβ-1 and α-1 particles. APOA2 concentration was positively correlated with preβ-1 particle functionality (ABCA1-CEC/mg APOA1 in preβ-1) (R2 = 0.42, p = 0.005), while APOE concentration was inversely correlated with large-HDL particle functionality (SRBI-CEC/mg APOA1 in α-1+α-2) (R2 = 0.18, p = 0.01).
CONCLUSIONS: The protein composition of the different HDL subpopulations was altered differentially in CHD patients. The functionality of the small and large HDL particles correlated with the protein content of APOA2 and APOE, respectively. Our data indicate that distinct particle subspecies and specific particle associated proteins provide new information about the role of HDL in CHD.
The invention discloses a cold-treatment traditional Chinese medicine capsule. The cold-treatment traditional Chinese medicine capsule is a pure traditional Chinese medicine preparation, is prepared from caulis lonicerae, wrinkled giant hyssop, herba schizonepetae, divaricate saposhnikovia root, perilla leaf, radix astragali and mint according to a certain weight ratio and total dosage, is in a form of decoction or capsule for oral administration and is a specific medicine for treating cold comprising influenza. One dosage of the cold-treatment traditional Chinese medicine capsule is used every day, and one dosage of the cold-treatment traditional Chinese medicine capsule can cure slight cold and 2-3 dosages of the cold-treatment traditional Chinese medicine capsule can cure bad cold. The cold-treatment traditional Chinese medicine capsule produces effects very fast. The cold-treatment traditional Chinese medicine in the form of decoction can immediately produce effects after drinking and can completely replace a western medicine antibiotic for treating cold comprising influenza. The cold-treatment traditional Chinese medicine capsule prevents patient health damage caused by abuse of antibiotic and provides a good technical support.
The present invention relates to compositions and methods for ablating tumor cells in a subject having at least one tumor site. More specifically, the method comprises contacting the tumor cells in at least one tumor with a lytic agent in vivo, under lytic conditions, forming a treated tumor; and applying a sufficient in vivo stimulus to the treated tumor forming a stimulated tumor. Compositions and methods are included for shrinking a local tumor or a distal metastatic tumor, or both in a subject. In a preferred embodiment, the method for shrinking a tumor in a subject comprises: contacting a stimulated tumor cells in vivo with a lytic agent. The stimulus directed toward the tumor cells is capable of increasing the level of chaperone proteins in the tumor cells. The combination of lytic agents and tumor cell stimulus leads to shrinkage of the tumors that were treated directly, wherein the stimulus is either applied simultaneously or sequentially. Moreover, distal or metastatic tumors that were not-treated directly are also decreased by introducing a lytic agents into a stimulated tumor cells in a first-tumor ('the treated tumor' or 'the local tumor'). The preferred method steps that include introduction of a lytic agent and stimulation of the tumor cells is repeated in order to maximize the tumor shrinkage effects.
- 80 -Abstract The present invention relates to a method for high throughput screening for a TCR- binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.- 80 -Abstract The present invention relates to a method for high throughput screening for a TCR- binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids. There are disclosed techniques for block wise encoding and decoding. The techniques may be applied to encoders, decoders, and methods for encoding and/or decoding. In one example, there is disclosed a decoder (54) for decoding a picture (10) from a data stream (12, 80). The decoder may be configured to predict a predetermined block (18) of the picture (10) by mapping a set of P neighboring samples (17'c, 17'a) neighboring the predetermined block (18) using a linear or affine linear transformation (17M) onto a set of Q predicted values for samples of the predetermined block (18). The linear or affine linear transformation (17M) may comprise P*Q weighting factors among which at least Â¼ P*Q weighting factors are non-zero weighting values, which comprise, for each of the Q predicted values, a series of P weighting factors relating to the respective predicted value, wherein the series, when being arranged one below the other according to a raster scan order among the samples of the predetermined block (18), form an envelope which is omnidirectionally non- linear.